Study Evaluating of Recombinant Human Factor IX (BeneFIX) and a New Formulation of BeneFIX (rFIX-R) in Moderate to Severe Hemophilia B

NCT00093210 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

INDUSTRY

Sponsor class

Conditions

Hemophilia B

Interventions

DRUG: rFIX
DRUG: rFIX-R

Sponsor

Wyeth is now a wholly owned subsidiary of Pfizer